Page 6 of 8
No serious side effects were reported during the double-blind phase of the study.
The table below shows the number of patients (percent) with non-serious side effects
reported during the double-blind phase.
Number of patients (percent) with non-serious side effects reported
during the double-blind phase
Placebo Mepolizumab
151 patients 144 patients
Injection site reaction 1 (less than 1%) 4 (3%)
Allergic reaction 0 1 (less than 1%)
Of the 295 patients included in the double-blind phase, 84 patients from the placebo
group and 45 patients from the mepolizumab group entered the open-label phase. No
serious side effects were reported during the open-label phase of the study.
The table below shows the number of patients (percent) with non-serious side effects
reported during the open-label phase.
Number of patients (percent) with non-serious side effects reported
during the open-label phase
Mepolizumab
129 patients
Feeling tired 1 (less than 1%)
Injection site reaction 1 (less than 1%)
Worsening symptoms of asthma 1 (less than 1%)
Rash 1 (less than 1%)